Current problems in cancer. Case reports最新文献_第5页

Refractory diarrhea in a patient with metastatic breast cancer with ABCB1 polymorphism: A case report ABCB1多态性转移性乳腺癌患者难治性腹泻1例报告

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-04-11 DOI: 10.1016/j.cpccr.2025.100367

Moeko Iida , Yoshihiko Tasaki , Akiko Kato , Tomoya Yasujima , Hiroaki Yuasa , Yasuhiro Maeda , Yoshihisa Mimura , Kunihiro Odagiri , Yuka Kimura , Nanami Ito , Yasuhiro Horita , Yosuke Sugiyama , Yuji Hotta , Tatsuya Toyama , Yoko Furukawa-Hibi

Although abemaciclib is an essential therapy for breast cancer, approximately 80 % of patients develop diarrhea. Abemaciclib undergoes excretion by the P-glycoprotein encoded by ATP-binding cassette subfamily B member 1 (ABCB1) in the small intestine during absorption. The polymorphism of this gene is associated with adverse effects such as pancytopenia. Therefore, we report a case of refractory diarrhea in which ABCB1 polymorphisms were investigated. A Japanese 44-year-old female was diagnosed with breast cancer (estrogen receptor positive, progesterone receptor positive, and human epidermal growth factor receptor 2-negative) accompanied with bone metastasis. Although the patient was initially treated with abemaciclib, letrozole (Femara), and leuprorelin, refractory diarrhea induced by abemaciclib occurred after six days of treatment. Serum abemaciclib concentrations were measured before and after the diarrhea alleviation and the ABCB1 (3435C>T, 1236T>C, and 2677G>T/A) polymorphisms involved in delayed abemaciclib excretion were examined. ABCB1 3435C>T polymorphism was also identified. The abemaciclib concentration prior to diarrhea alleviation was higher than the mean concentration in a large-scale clinical trial (current study; 326.7 ng/mL vs a large-scale clinical trial; 169–243 ng/mL). The patient discontinued abemaciclib as it was difficult for her to continue the dose (150 mg twice daily) because of the associated diarrhea, which was alleviated thereafter. The abemaciclib concentration after diarrhea alleviation was below the detection limit of 25.0 ng/mL. ABCB1 3435C>T polymorphism may be involved in the induction of refractory diarrhea by abemaciclib and may be an objective indicator for managing abemaciclib dosage.

虽然abemaciclib是乳腺癌的基本治疗方法，但大约80%的患者会出现腹泻。Abemaciclib在小肠吸收过程中由atp结合盒B亚家族成员1 （ABCB1）编码的p糖蛋白排泄。该基因的多态性与全血细胞减少症等不良反应有关。因此，我们报告了一例难治性腹泻，其中ABCB1多态性进行了调查。一位44岁的日本女性被诊断为乳腺癌（雌激素受体阳性，孕激素受体阳性，人表皮生长因子受体2阴性）并伴有骨转移。尽管患者最初接受了abemaciclib、来曲唑（Femara）和leuprorelin的治疗，但在治疗6天后，abemaciclib引起了难治性腹泻。测定腹泻缓解前后血清abemaciclib浓度，并检测ABCB1 （3435C>；T, 1236T>；C, 2677G>T/A）多态性与abemaciclib延迟排泄有关。ABCB1 3435C>；T多态性也被鉴定出来。腹泻缓解前的abemaciclib浓度高于大规模临床试验的平均浓度(当前研究；326.7 ng/mL vs大规模临床试验；169 - 243 ng / mL)。患者停用abemaciclib，因为伴随腹泻难以继续服用（150mg，每日两次），此后腹泻有所缓解。腹泻缓解后abemaciclib浓度低于25.0 ng/mL的检出限。ABCB1 3435C>；T多态性可能参与abemaciclib诱导难治性腹泻，可能是控制abemaciclib剂量的客观指标。

{"title":"Refractory diarrhea in a patient with metastatic breast cancer with ABCB1 polymorphism: A case report","authors":"Moeko Iida , Yoshihiko Tasaki , Akiko Kato , Tomoya Yasujima , Hiroaki Yuasa , Yasuhiro Maeda , Yoshihisa Mimura , Kunihiro Odagiri , Yuka Kimura , Nanami Ito , Yasuhiro Horita , Yosuke Sugiyama , Yuji Hotta , Tatsuya Toyama , Yoko Furukawa-Hibi","doi":"10.1016/j.cpccr.2025.100367","DOIUrl":"10.1016/j.cpccr.2025.100367","url":null,"abstract":"<div><div>Although abemaciclib is an essential therapy for breast cancer, approximately 80 % of patients develop diarrhea. Abemaciclib undergoes excretion by the P-glycoprotein encoded by ATP-binding cassette subfamily B member 1 (<em>ABCB1</em>) in the small intestine during absorption. The polymorphism of this gene is associated with adverse effects such as pancytopenia. Therefore, we report a case of refractory diarrhea in which <em>ABCB1</em> polymorphisms were investigated. A Japanese 44-year-old female was diagnosed with breast cancer (estrogen receptor positive, progesterone receptor positive, and human epidermal growth factor receptor 2-negative) accompanied with bone metastasis. Although the patient was initially treated with abemaciclib, letrozole (Femara), and leuprorelin, refractory diarrhea induced by abemaciclib occurred after six days of treatment. Serum abemaciclib concentrations were measured before and after the diarrhea alleviation and the <em>ABCB1</em> (3435C><em>T</em>, 1236T><em>C</em>, and 2677G><em>T</em>/A) polymorphisms involved in delayed abemaciclib excretion were examined. <em>ABCB1</em> 3435C><em>T</em> polymorphism was also identified. The abemaciclib concentration prior to diarrhea alleviation was higher than the mean concentration in a large-scale clinical trial (current study; 326.7 ng/mL vs a large-scale clinical trial; 169–243 ng/mL). The patient discontinued abemaciclib as it was difficult for her to continue the dose (150 mg twice daily) because of the associated diarrhea, which was alleviated thereafter. The abemaciclib concentration after diarrhea alleviation was below the detection limit of 25.0 ng/mL. <em>ABCB1</em> 3435C><em>T</em> polymorphism may be involved in the induction of refractory diarrhea by abemaciclib and may be an objective indicator for managing abemaciclib dosage.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100367"},"PeriodicalIF":0.2,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3D printed lightweight breast prostheses for a patient of breast size 38F who was unhappy with the heavy weight of their silicone prosthesis 3D打印轻量级乳房假体为乳房大小38F的患者谁是不满意他们的硅胶假体的重量

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-04-08 DOI: 10.1016/j.cpccr.2025.100366

Lyons EmmaJude , Baban Chwanrow , Walsh Lorraine , O'Sullivan Kevin.J , O'Sullivan Aidan , Meany Siobhan , O'Sullivan Leonard W

Breast prostheses offer symmetry and femininity restoration for women post-mastectomy. They are fitted to an individual's bra size, but standard prostheses can be heavy and uncomfortable on the scar site. Custom-made breast prosthesis offers improved fit, contour matching, and reduced weight, which is beneficial to patients. We report a case of a specific patient with a large prosthesis who experienced significant comfort issues with her standard silicone prosthesis, and how a bespoke prosthesis was created from a scan of her residual contralateral breast and created using 3D printing such that it was lightweight.

Two 3D scans were taken, one of the patient's residual contralateral breast while wearing a comfortable and well-fitting bra, and the other of the mastectomy site. The scans were processed using STL file editing software Meshmixer and Nomad Sculpt, and the residual breast profile was isolated and mirrored across the centerline of the patient's body. This profile was then aligned with the mastectomy surgery site scan and combined to create the anterior side of the prosthesis. A Vat Polymerisation (VP) 3D printing technology was used to produce the breast prosthesis, which was 3D printed on a FormLabs 3B+ using the FormLabs Flexible 80A material.

The new 3d printed prosthesis design is lightweight and flexible and mirrors the existing breast to achieve anatomical symmetry. The bespoke prosthesis is 62 % lighter than the patient's previous silicone prosthesis. Additionally, the anterior of the prosthesis is a bespoke match of the mastectomy scar site, providing for a secure fit.

The patient has worn her custom-made breast prosthesis for over one year up to the time of writing, and continues to do so. She describes the prosthesis as comfortable, lightweight, and secure in her bra. The use of 3D printing presents an opportunity to enhance the quality of breast prosthesis according to individual patient preferences.

乳房假体为乳房切除术后的女性提供对称和女性气质的恢复。它们适合每个人的胸罩尺寸，但标准的假体在疤痕部位可能很重，而且不舒服。定制的乳房假体改善了乳房的贴合度，轮廓匹配，减轻了重量，对患者有益。我们报告了一个案例，一个特定的病人有一个大的假体，她的标准硅胶假体经历了明显的舒适问题，以及如何从她的残余对侧乳房的扫描中创建一个定制的假体，并使用3D打印创建，这样它是轻量级的。进行了两次3D扫描，其中一次是患者穿着舒适合身的胸罩时的对侧乳房残余，另一次是乳房切除术部位。使用STL文件编辑软件Meshmixer和Nomad sculppt对扫描结果进行处理，将残留的乳房轮廓分离出来，并在患者身体的中心线上镜像。然后将该轮廓与乳房切除术手术部位扫描对齐，并结合起来创建假体的前部。采用大桶聚合（VP） 3D打印技术生产乳房假体，使用FormLabs Flexible 80A材料在FormLabs 3B+上进行3D打印。新的3d打印假体设计轻巧灵活，并反映了现有的乳房，以达到解剖对称。定制的假体比患者以前的硅胶假体轻62%。此外，假体的前部是乳房切除术疤痕部位的定制匹配，提供了一个安全的配合。到撰写本文时，患者已佩戴定制乳房假体一年多，并将继续佩戴。她说这个假体舒适、轻便，而且放在胸罩里很安全。3D打印的使用提供了一个机会来提高乳房假体的质量，根据个别患者的喜好。

{"title":"3D printed lightweight breast prostheses for a patient of breast size 38F who was unhappy with the heavy weight of their silicone prosthesis","authors":"Lyons EmmaJude , Baban Chwanrow , Walsh Lorraine , O'Sullivan Kevin.J , O'Sullivan Aidan , Meany Siobhan , O'Sullivan Leonard W","doi":"10.1016/j.cpccr.2025.100366","DOIUrl":"10.1016/j.cpccr.2025.100366","url":null,"abstract":"<div><div>Breast prostheses offer symmetry and femininity restoration for women post-mastectomy. They are fitted to an individual's bra size, but standard prostheses can be heavy and uncomfortable on the scar site. Custom-made breast prosthesis offers improved fit, contour matching, and reduced weight, which is beneficial to patients. We report a case of a specific patient with a large prosthesis who experienced significant comfort issues with her standard silicone prosthesis, and how a bespoke prosthesis was created from a scan of her residual contralateral breast and created using 3D printing such that it was lightweight.</div><div>Two 3D scans were taken, one of the patient's residual contralateral breast while wearing a comfortable and well-fitting bra, and the other of the mastectomy site. The scans were processed using STL file editing software Meshmixer and Nomad Sculpt, and the residual breast profile was isolated and mirrored across the centerline of the patient's body. This profile was then aligned with the mastectomy surgery site scan and combined to create the anterior side of the prosthesis. A Vat Polymerisation (VP) 3D printing technology was used to produce the breast prosthesis, which was 3D printed on a FormLabs 3B+ using the FormLabs Flexible 80A material.</div><div>The new 3d printed prosthesis design is lightweight and flexible and mirrors the existing breast to achieve anatomical symmetry. The bespoke prosthesis is 62 % lighter than the patient's previous silicone prosthesis. Additionally, the anterior of the prosthesis is a bespoke match of the mastectomy scar site, providing for a secure fit.</div><div>The patient has worn her custom-made breast prosthesis for over one year up to the time of writing, and continues to do so. She describes the prosthesis as comfortable, lightweight, and secure in her bra. The use of 3D printing presents an opportunity to enhance the quality of breast prosthesis according to individual patient preferences.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100366"},"PeriodicalIF":0.2,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary lymphangitic carcinomatosis secondary to gastric Cancer in a Young Woman: A case report 一名年轻女性继发于胃癌的肺淋巴管癌肿：病例报告

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-04-01 DOI: 10.1016/j.cpccr.2025.100365

Sijie Liu, Jing Wang

Background

Pulmonary lymphangitic carcinomatosis (PLC) is a rare secondary metastatic cancer. Cough and dyspnea are the common clinical manifestations of PLC. PLC is often confused with pulmonary sarcoidosis, pulmonary edema, pneumoconiosis, and interstitial pneumonia, which leads to delayed diagnosis and poor prognosis.

Case Presentation

A 23-year-old female with a cough. Gastric cancer was confirmed by gastroscopy. The abnormal changes in the lung were considered to be consistent with PLC.

Conclusion

PCL is often misdiagnosed or delayed. PLC should be considered when cough, dyspnea, and chest CT show thickening of the peribronchovascular and interlobular septa or when pleural effusion and enlargement of mediastinal lymph nodes.

背景：肺淋巴管癌是一种罕见的继发性转移性癌症。咳嗽和呼吸困难是PLC的常见临床表现。PLC常与肺结节病、肺水肿、尘肺病和间质性肺炎相混淆，导致诊断延误和预后不良。病例表现：23岁女性，咳嗽。胃镜检查证实为胃癌。肺部的异常变化被认为与PLC一致。结论pcl常被误诊或延误。当咳嗽、呼吸困难、胸部CT显示支气管血管周围和小叶间隔增厚或胸膜积液和纵隔淋巴结肿大时，应考虑PLC。

引用次数: 0

Intrasplenic metastasis of appendiceal low-grade mucinous neoplasm – A case report and review of the literature 阑尾低级别黏液性肿瘤脾内转移1例并文献复习

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-03-23 DOI: 10.1016/j.cpccr.2025.100364

P. Meister , J. Rawitzer , M. Reschke , H.A. Baba , U. Neumann , M. Kaths

Low-grade appendiceal mucinous neoplasms (LAMNs) may lead to pseudomyxoma peritonei and require specialized surgical therapy. By pathological definition, these tumor entities exhibit neither invasive growth nor develop systemic or lymph node metastases. We report the case of a 43-year-old female presenting with a metachronous splenic metastasis of low-grade pseudomyxoma peritonei four years after surgical therapy. The patient was treated successfully via laparoscopic splenectomy. While the spleen itself is an extremely rare location for metastasizing colonic cancer, a LAMN metastasis in this location has not been previously described. A literature review of pseudomyxoma recurrence reveals that LAMNs might indeed recur in extraperitoneal locations, questioning their pathophysiological definition of non-metastasizing behavior.

低级别阑尾黏液性肿瘤（lamn）可能导致腹膜假性黏液瘤，需要专门的手术治疗。根据病理学定义，这些肿瘤实体既没有侵袭性生长，也没有发展成全身或淋巴结转移。我们报告一例43岁女性在手术治疗4年后出现低级别腹膜假性黏液瘤的异时性脾转移。经腹腔镜脾切除术治疗成功。虽然脾脏本身是一个极其罕见的转移结肠癌的位置，LAMN在这个位置的转移以前没有被描述过。一篇关于假性黏液瘤复发的文献综述显示，lamn确实可能在腹膜外部位复发，这对其非转移行为的病理生理学定义提出了质疑。

引用次数: 0

Clear cell sarcoma of salivary gland: A case report 唾液腺透明细胞肉瘤1例

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-03-17 DOI: 10.1016/j.cpccr.2025.100359

Saša Z. Tabaković , Sonja Tabaković

Introduction

Malignant mesenchymal tumors of the salivary glands are neoplasms whose histopathological picture represents a very big diagnostic challenge. Most tumors of the parotid glands are benign, and for malignant neoplasms, immunohistochemistry is essential for diagnosis.

Aim

The aim is to present a rare case of a mesenchymal malignant tumor of the parotid gland, including diagnostics and surgical therapy.

Case presentation

A 67-year-old patient presented with a tumor around the parotid gland. Sonographically, the change resembled an adenoma, although the differential diagnosis did not exclude a pathological entity of another etiology. The patient underwent a superficial parotidectomy, and the operative and postoperative course was without complications. Immunohistochemical analysis in combine with histopath results confirmed the final diagnosis of Clear Cell Sarcoma of the parotid gland.

Conclusion

Clear cell sarcoma of the parotid gland is a rare malignant neoplasm. Timely diagnosis and total parotidectomy with negative resection margins, in the first year after the operation ensure a satisfactory postoperative result without recurrence and meta-changes. Doctors should be very cautious in such situations because the histopathological examination with immunohistochemical analysis gives a clear picture of the tumor in question as a differential diagnosis.

唾液腺恶性间充质瘤是一种组织病理学图像对诊断具有很大挑战的肿瘤。大多数腮腺肿瘤是良性的，对于恶性肿瘤，免疫组织化学是诊断的必要条件。目的报告一例罕见的腮腺间充质恶性肿瘤，包括诊断和手术治疗。病例介绍：一位67岁的患者，在腮腺周围发现肿瘤。超声检查，改变类似于腺瘤，虽然鉴别诊断不能排除其他病因的病理实体。患者行腮腺浅表切除术，手术及术后无并发症。免疫组化分析结合组织病理学结果证实了腮腺透明细胞肉瘤的最终诊断。结论腮腺透明细胞肉瘤是一种罕见的恶性肿瘤。术后一年内及时诊断并行阴性切缘全腮腺切除术，可确保术后无复发及meta改变。在这种情况下，医生应该非常谨慎，因为组织病理学检查和免疫组织化学分析提供了肿瘤的清晰图像，作为鉴别诊断。

{"title":"Clear cell sarcoma of salivary gland: A case report","authors":"Saša Z. Tabaković , Sonja Tabaković","doi":"10.1016/j.cpccr.2025.100359","DOIUrl":"10.1016/j.cpccr.2025.100359","url":null,"abstract":"<div><h3>Introduction</h3><div>Malignant mesenchymal tumors of the salivary glands are neoplasms whose histopathological picture represents a very big diagnostic challenge. Most tumors of the parotid glands are benign, and for malignant neoplasms, immunohistochemistry is essential for diagnosis.</div></div><div><h3>Aim</h3><div>The aim is to present a rare case of a mesenchymal malignant tumor of the parotid gland, including diagnostics and surgical therapy.</div></div><div><h3>Case presentation</h3><div>A 67-year-old patient presented with a tumor around the parotid gland. Sonographically, the change resembled an adenoma, although the differential diagnosis did not exclude a pathological entity of another etiology. The patient underwent a superficial parotidectomy, and the operative and postoperative course was without complications. Immunohistochemical analysis in combine with histopath results confirmed the final diagnosis of Clear Cell Sarcoma of the parotid gland.</div></div><div><h3>Conclusion</h3><div>Clear cell sarcoma of the parotid gland is a rare malignant neoplasm. Timely diagnosis and total parotidectomy with negative resection margins, in the first year after the operation ensure a satisfactory postoperative result without recurrence and meta-changes. Doctors should be very cautious in such situations because the histopathological examination with immunohistochemical analysis gives a clear picture of the tumor in question as a differential diagnosis.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100359"},"PeriodicalIF":0.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The successful employment of Brentuximab Vedotin to a patient with peritoneal dialysis: A case report 布伦妥昔单抗韦多汀对腹膜透析患者的成功应用：一例报告

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-03-15 DOI: 10.1016/j.cpccr.2025.100363

Sunpil Hwang , Sucheta Kundu , Brett Barlow

Brentuximab Vedotin, an antibody-drug conjugate targeting CD30, has been widely used in treating systemic anaplastic large-cell lymphoma and primary cutaneous anaplastic large-cell lymphoma. Despite its extensive use, information on its use in patients with end-stage renal disease is limited. This case report illustrates a 75-year-old male undergoing daily peritoneal dialysis, diagnosed with primary cutaneous anaplastic large-cell lymphoma. Due to extensive lesions, the patient opted for Brentuximab Vedotin following an exhaustive discussion. Remarkably, the treatment resulted in the complete resolution of cutaneous lesions, which was confirmed by a subsequent negative PET scan, indicating the absence of malignancy. Throughout the treatment course, the patient reported only weakness as a side effect, which was compounded by an acute COVID-19 infection at that time. This case report underscores the potential application of Brentuximab Vedotin in patients undergoing peritoneal dialysis, a population previously excluded, thus providing another promising therapeutic option for this particular population.

Brentuximab Vedotin是一种靶向CD30的抗体-药物偶联物，广泛用于治疗全身性间变性大细胞淋巴瘤和原发性皮肤间变性大细胞淋巴瘤。尽管其广泛使用，但其在终末期肾病患者中的应用信息有限。本病例报告显示一75岁男性每日接受腹膜透析，诊断为原发性皮肤间变性大细胞淋巴瘤。由于广泛的病变，在详尽的讨论后，患者选择Brentuximab Vedotin。值得注意的是，治疗导致皮肤病变完全消退，随后的PET阴性扫描证实了这一点，表明没有恶性肿瘤。在整个治疗过程中，患者只报告了虚弱的副作用，当时又出现了急性COVID-19感染。本病例报告强调Brentuximab Vedotin在腹膜透析患者中的潜在应用，这一人群以前被排除在外，因此为这一特定人群提供了另一种有希望的治疗选择。

{"title":"The successful employment of Brentuximab Vedotin to a patient with peritoneal dialysis: A case report","authors":"Sunpil Hwang , Sucheta Kundu , Brett Barlow","doi":"10.1016/j.cpccr.2025.100363","DOIUrl":"10.1016/j.cpccr.2025.100363","url":null,"abstract":"<div><div>Brentuximab Vedotin, an antibody-drug conjugate targeting CD30, has been widely used in treating systemic anaplastic large-cell lymphoma and primary cutaneous anaplastic large-cell lymphoma. Despite its extensive use, information on its use in patients with end-stage renal disease is limited. This case report illustrates a 75-year-old male undergoing daily peritoneal dialysis, diagnosed with primary cutaneous anaplastic large-cell lymphoma. Due to extensive lesions, the patient opted for Brentuximab Vedotin following an exhaustive discussion. Remarkably, the treatment resulted in the complete resolution of cutaneous lesions, which was confirmed by a subsequent negative PET scan, indicating the absence of malignancy. Throughout the treatment course, the patient reported only weakness as a side effect, which was compounded by an acute COVID-19 infection at that time. This case report underscores the potential application of Brentuximab Vedotin in patients undergoing peritoneal dialysis, a population previously excluded, thus providing another promising therapeutic option for this particular population.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100363"},"PeriodicalIF":0.2,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recurrent primary pulmonary anaplastic B-cell lymphoma in a 35-year-old patient treated with radical resection: A case report. 35岁原发性肺间变性b细胞淋巴瘤根治性切除复发1例。

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-03-01 DOI: 10.1016/j.cpccr.2025.100362

George Bashour , Muhsen Issa , Saddik Haddad , Gabi Kafa , Hussein Kaada , Samer Rajab , Ali Daoud , Rabab Salloum

Background

Primary pulmonary lymphoma (PPL) is a lymphoid proliferation in the lung parenchyma and/or bronchi of a patient with no extrapulmonary lesion within 3 months of diagnosis. Diffuse large B-cell lymphoma (DLBCL) accounts for 10 % of all PPL cases, and only a very minor number of them present with an anaplastic morphologic variant.

Case presentation

We report a 35-year-old female patient who presented with shortness of breath, cough, anorexia, weight loss, fever of unknown origin, and night sweats. The patient was diagnosed with primary pulmonary anaplastic DLBCL and put on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen. She achieved remission according to the PET scan results; however, the symptoms recurred one year later, and a CT scan confirmed the regrowth of the tumor. The patient refused further chemotherapy and repeated the biopsy at another center, and she was diagnosed with Hodgkin lymphoma and was placed on ifosfamide, carboplatin, and etoposide (ICE) and rituximab, dexamethasone, cytarabine, and cysplatin (RDHAP) protocols for 9 months, which did not improve her condition. Finally, a PET scan revealed that the lesion was limited to the lung with no visible metastases or lymph node involvement, and radical surgery was performed to excise the tumor. A new IHC panel was ordered because of the conflicting reports, and it showed matching results to the first diagnosis, except for a negative CD20 result, which was attributed to rituximab in the patient's chemotherapy. A 2-year follow-up revealed no lesions or recurrence.

Conclusion

DLBCL is an uncommon cause for primary lung lymphomas, but high clinical suspicion must be maintained when assessing such tumors, even among younger individuals. More studies should be done to investigate the best treatment option for the anaplastic variant of DLBCL.

背景：原发性肺淋巴瘤（PPL）是在诊断后3个月内无肺外病变的患者肺实质和/或支气管的淋巴样增生。弥漫性大b细胞淋巴瘤（DLBCL）占所有PPL病例的10%，其中只有极少数表现为间变性形态变异。我们报告一位35岁女性患者，她表现为呼吸短促、咳嗽、厌食、体重减轻、不明原因发热和盗汗。患者诊断为原发性肺间变性DLBCL，给予利妥昔单抗、环磷酰胺、阿霉素、长春新碱、强的松（R-CHOP）治疗。根据PET扫描结果，她获得缓解；然而，一年后症状再次出现，CT扫描证实肿瘤再次生长。患者拒绝进一步化疗，并在另一个中心重复活检，她被诊断为霍奇金淋巴瘤，并接受异环磷酰胺、卡铂和依托泊苷（ICE）和利妥昔单抗、地塞米松、阿糖胞苷和顺铂（RDHAP）治疗9个月，但病情没有改善。最后，PET扫描显示病变局限于肺部，没有可见的转移或淋巴结受累，并进行根治性手术切除肿瘤。由于相互矛盾的报告，要求进行新的免疫组化检查，结果显示与第一次诊断结果相符，除了CD20结果为阴性，这归因于患者化疗中的利妥昔单抗。2年随访未见病变或复发。结论dlbcl是原发性肺淋巴瘤的罕见病因，但在评估此类肿瘤时必须保持高度的临床怀疑，即使在年轻人中也是如此。应该做更多的研究来研究DLBCL间变性的最佳治疗方案。

{"title":"Recurrent primary pulmonary anaplastic B-cell lymphoma in a 35-year-old patient treated with radical resection: A case report.","authors":"George Bashour , Muhsen Issa , Saddik Haddad , Gabi Kafa , Hussein Kaada , Samer Rajab , Ali Daoud , Rabab Salloum","doi":"10.1016/j.cpccr.2025.100362","DOIUrl":"10.1016/j.cpccr.2025.100362","url":null,"abstract":"<div><h3>Background</h3><div>Primary pulmonary lymphoma (PPL) is a lymphoid proliferation in the lung parenchyma and/or bronchi of a patient with no extrapulmonary lesion within 3 months of diagnosis. Diffuse large B-cell lymphoma (DLBCL) accounts for 10 % of all PPL cases, and only a very minor number of them present with an anaplastic morphologic variant.</div></div><div><h3>Case presentation</h3><div>We report a 35-year-old female patient who presented with shortness of breath, cough, anorexia, weight loss, fever of unknown origin, and night sweats. The patient was diagnosed with primary pulmonary anaplastic DLBCL and put on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen. She achieved remission according to the PET scan results; however, the symptoms recurred one year later, and a CT scan confirmed the regrowth of the tumor. The patient refused further chemotherapy and repeated the biopsy at another center, and she was diagnosed with Hodgkin lymphoma and was placed on ifosfamide, carboplatin, and etoposide (ICE) and rituximab, dexamethasone, cytarabine, and cysplatin (RDHAP) protocols for 9 months, which did not improve her condition. Finally, a PET scan revealed that the lesion was limited to the lung with no visible metastases or lymph node involvement, and radical surgery was performed to excise the tumor. A new IHC panel was ordered because of the conflicting reports, and it showed matching results to the first diagnosis, except for a negative CD20 result, which was attributed to rituximab in the patient's chemotherapy. A 2-year follow-up revealed no lesions or recurrence.</div></div><div><h3>Conclusion</h3><div>DLBCL is an uncommon cause for primary lung lymphomas, but high clinical suspicion must be maintained when assessing such tumors, even among younger individuals. More studies should be done to investigate the best treatment option for the anaplastic variant of DLBCL.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100362"},"PeriodicalIF":0.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Possible secondary angiosarcoma following subcutaneous mastectomy with primary reconstruction without subsequent radiotherapy: A case report and literature review 乳房皮下切除术后无放疗重建可能继发血管肉瘤：1例报告及文献复习

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-03-01 DOI: 10.1016/j.cpccr.2025.100358

David Ibsen Dadash-Khanlou , Hanne Rønning , Helga Fibiger Munch-Petersen , Ida Lolle , Sandra Duvnjak , Bodil Elisabeth Engelmann , Elisabeth Ida Specht Stovgaard

Angiosarcoma is a rare aggressive tumor of the endothelial cells, that in its secondary form can be seen in breast cancer patients 5–10 years following radiation therapy or radical mastectomy with chronic lymphedema. In this article, we report a rare case of a breast cancer patient developing possible secondary angiosarcoma following surgery while having received no subsequent radiation therapy.

A 66-year-old female presented in 2016 with invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS) in her right breast. She was treated with a subcutaneous mastectomy and primary reconstruction using a DIEP-flap (deep inferior epigastric perforator flap). She received postoperative adjuvant chemotherapy combined with HER2 targeted therapy, but no radiation therapy. In 2023, the patient presented with yellowish marks on the reconstructed breast and a history of trauma to the right side of her body, suggestive of hematoma. Clinical mammography and fine needle aspiration showed only reactive changes. In the following months the cutaneous changes worsened with ulceration, discoloration, and bleeding in the reconstructed breast. A core needle biopsy was taken and angiosarcoma with high malignancy grade was found.

Microscopically, the tumor was composed of malignant mesenchymal spindle cells in a hypercellular and slit-like pattern with numerous mitotic figures and nuclear pleomorphism with oval and enlarged nucleoli. Immunohistochemical stain was strongly positive of CD34, CD31 and, remarkably, c-Myc. There was no expression of D240, cytokeratin or S-100.

The case highlights that angiosarcoma cannot be excluded in patients following extensive surgery and that we must be aware of this risk in the future.

血管肉瘤是一种罕见的侵袭性内皮细胞肿瘤，其继发形式可见于放射治疗或根治性乳房切除术后5-10年伴有慢性淋巴水肿的乳腺癌患者。在这篇文章中，我们报告了一例罕见的乳腺癌患者在手术后发生继发性血管肉瘤，而没有接受后续的放射治疗。一名66岁女性于2016年因右乳浸润性导管癌（IDC）和导管原位癌（DCIS）而入院。她接受了皮下乳房切除术和diep皮瓣（深下腹部穿支皮瓣）的初步重建。术后行辅助化疗联合HER2靶向治疗，未行放疗。2023年，患者重建乳房出现淡黄色印记，右侧身体有创伤史，提示血肿。临床乳房x线摄影和细针穿刺仅显示反应性改变。在接下来的几个月里，皮肤的改变随着重建乳房的溃疡、变色和出血而恶化。行核心穿刺活检，发现高恶性等级血管肉瘤。显微镜下，肿瘤由恶性间充质梭形细胞组成，呈高细胞裂缝状，有丝分裂象众多，核多形性，核仁卵圆形，增大。免疫组化染色显示CD34、CD31和c-Myc强烈阳性。D240、细胞角蛋白、S-100均未表达。该病例强调血管肉瘤不能排除在广泛手术后的患者中，我们必须在未来意识到这种风险。

{"title":"Possible secondary angiosarcoma following subcutaneous mastectomy with primary reconstruction without subsequent radiotherapy: A case report and literature review","authors":"David Ibsen Dadash-Khanlou , Hanne Rønning , Helga Fibiger Munch-Petersen , Ida Lolle , Sandra Duvnjak , Bodil Elisabeth Engelmann , Elisabeth Ida Specht Stovgaard","doi":"10.1016/j.cpccr.2025.100358","DOIUrl":"10.1016/j.cpccr.2025.100358","url":null,"abstract":"<div><div>Angiosarcoma is a rare aggressive tumor of the endothelial cells, that in its secondary form can be seen in breast cancer patients 5–10 years following radiation therapy or radical mastectomy with chronic lymphedema. In this article, we report a rare case of a breast cancer patient developing possible secondary angiosarcoma following surgery while having received no subsequent radiation therapy.</div><div>A 66-year-old female presented in 2016 with invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS) in her right breast. She was treated with a subcutaneous mastectomy and primary reconstruction using a DIEP-flap (deep inferior epigastric perforator flap). She received postoperative adjuvant chemotherapy combined with HER2 targeted therapy, but no radiation therapy. In 2023, the patient presented with yellowish marks on the reconstructed breast and a history of trauma to the right side of her body, suggestive of hematoma. Clinical mammography and fine needle aspiration showed only reactive changes. In the following months the cutaneous changes worsened with ulceration, discoloration, and bleeding in the reconstructed breast. A core needle biopsy was taken and angiosarcoma with high malignancy grade was found.</div><div>Microscopically, the tumor was composed of malignant mesenchymal spindle cells in a hypercellular and slit-like pattern with numerous mitotic figures and nuclear pleomorphism with oval and enlarged nucleoli. Immunohistochemical stain was strongly positive of CD34, CD31 and, remarkably, c-Myc. There was no expression of D240, cytokeratin or S-100.</div><div>The case highlights that angiosarcoma cannot be excluded in patients following extensive surgery and that we must be aware of this risk in the future.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100358"},"PeriodicalIF":0.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary squamous cell carcinoma complicated with invasive ductal carcinoma of breast 原发性鳞状细胞癌合并浸润性乳腺导管癌

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-03-01 DOI: 10.1016/j.cpccr.2025.100361

Chen Fan , Linhui Fang , Li Yang , Fan Wang

Background

Primary Squamous Cell Carcinoma (SCC) of the breast, a rare subtype of metaplastic carcinoma, is estimated to occur in <0.1 % of breast cancer cases. In clinical practice, the coexistence of primary SCC with Invasive Ductal Carcinoma (IDC) is exceptionally rare, presenting unique challenges in diagnosis and management.

Case report

We report a patient with primary SCC complicated with IDC of the breast. This patient underwent operation, adjuvant chemotherapy and endocrine therapy according to the Breast Cancer Guidelines.

Conclusion

Primary SCC of the breast is recognized for its highly aggressive nature and resistance to treatment, often associated with a poor prognosis. Currently, there are no specific guidelines dedicated to the management of primary SCC of the breast. When primary SCC coexists with IDC of the breast, the prognosis becomes even more uncertain due to the complex interplay between these two distinct pathological entities. In this case, we have adopted a treatment strategy targeting the IDC component, following established guidelines for breast cancer management. We anticipate that this approach will contribute to a favorable prognosis for the patient.

背景：乳腺原发性鳞状细胞癌（SCC）是一种罕见的化生癌亚型，估计发生在0.1%的乳腺癌病例中。在临床实践中，原发性鳞状细胞癌与浸润性导管癌（Invasive Ductal Carcinoma， IDC）共存的情况非常罕见，这给诊断和治疗带来了独特的挑战。病例报告我们报告了一例原发性鳞状细胞癌合并乳腺IDC的病例。根据乳腺癌指南，患者接受了手术、辅助化疗和内分泌治疗。结论原发性乳腺鳞状细胞癌具有很强的侵袭性和耐治疗性，预后较差。目前，尚无专门针对乳腺原发性鳞状细胞癌治疗的具体指南。当原发性鳞状细胞癌与乳腺IDC共存时，由于这两种不同病理实体之间复杂的相互作用，预后变得更加不确定。在这种情况下，我们采用了针对IDC组件的治疗策略，遵循既定的乳腺癌管理指南。我们预计这种方法将有助于患者的良好预后。

{"title":"Primary squamous cell carcinoma complicated with invasive ductal carcinoma of breast","authors":"Chen Fan , Linhui Fang , Li Yang , Fan Wang","doi":"10.1016/j.cpccr.2025.100361","DOIUrl":"10.1016/j.cpccr.2025.100361","url":null,"abstract":"<div><h3>Background</h3><div>Primary Squamous Cell Carcinoma (SCC) of the breast, a rare subtype of metaplastic carcinoma, is estimated to occur in <0.1 % of breast cancer cases. In clinical practice, the coexistence of primary SCC with Invasive Ductal Carcinoma (IDC) is exceptionally rare, presenting unique challenges in diagnosis and management.</div></div><div><h3>Case report</h3><div>We report a patient with primary SCC complicated with IDC of the breast. This patient underwent operation, adjuvant chemotherapy and endocrine therapy according to the Breast Cancer Guidelines.</div></div><div><h3>Conclusion</h3><div>Primary SCC of the breast is recognized for its highly aggressive nature and resistance to treatment, often associated with a poor prognosis. Currently, there are no specific guidelines dedicated to the management of primary SCC of the breast. When primary SCC coexists with IDC of the breast, the prognosis becomes even more uncertain due to the complex interplay between these two distinct pathological entities. In this case, we have adopted a treatment strategy targeting the IDC component, following established guidelines for breast cancer management. We anticipate that this approach will contribute to a favorable prognosis for the patient.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100361"},"PeriodicalIF":0.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unanticipated recurrence of muscle-invasive bladder cancer: A case report 肌肉浸润性膀胱癌意外复发1例

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-02-19 DOI: 10.1016/j.cpccr.2025.100357

Farzad Allameh , Afshin Moradi , Azadeh Rakhshan , Sina Samenezhad , Amir Alinejad Khorram

Muscle-invasive bladder cancer management often involves radical cystectomy, but bladder preservation protocols have gained recognition as a low-morbidity alternative for the management of carefully selected patients. However, close follow-up is crucial for prompt diagnosis of cancer recurrence. We report a case of muscle-invasive bladder cancer managed using a bladder preservation approach. Although cystoscopy and random biopsy findings appeared unremarkable during follow-up, tumor recurrence occurred in the muscular propria without involving the bladder mucosa. This case underscores the importance of revising follow-up protocols to ensure optimal patient care.

肌肉侵袭性膀胱癌的治疗通常涉及根治性膀胱切除术，但膀胱保存方案已被公认为是一种低发病率的选择，可用于精心挑选的患者的治疗。然而，密切的随访对于及时诊断癌症复发至关重要。我们报告一例肌肉侵袭性膀胱癌的管理使用膀胱保存方法。尽管膀胱镜检查和随机活检结果在随访中未见明显变化，但肿瘤复发发生在肌肉固有层，未累及膀胱粘膜。该病例强调了修订随访方案以确保最佳患者护理的重要性。

引用次数: 0